# A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct04175600` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04175600](<https://clinicaltrials.gov/study/NCT04175600>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04175600

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 138 participants.

## Technical summary

Registry record NCT04175600. Randomized; double masking; primary purpose treatment. Start 2020-01-16 (actual); primary completion 2024-10-11 (actual). Results posted on 2026-07-20.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 138 participants (enrolled count; ClinicalTrials.gov record NCT04175600, source copy `cardio:ctgov-nct04175600-2026-11-03`, retrieved 2026-11-18)
- Started: 2020-01-16 (actual) (ClinicalTrials.gov record NCT04175600, source copy `cardio:ctgov-nct04175600-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2024-10-11 (actual) (ClinicalTrials.gov record NCT04175600, source copy `cardio:ctgov-nct04175600-2026-11-03`, retrieved 2026-11-18)
- Completion: 2027-10-01 (anticipated) (ClinicalTrials.gov record NCT04175600, source copy `cardio:ctgov-nct04175600-2026-11-03`, retrieved 2026-11-18)
- Results first posted: 2026-07-20 (ClinicalTrials.gov record NCT04175600, source copy `cardio:ctgov-nct04175600-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Australia; Belarus; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Finland; France; Germany; Hungary; Ireland; Israel; Italy; Lithuania; Malaysia; Mexico; Poland; Portugal; Russia; Serbia; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; Ukraine; Vietnam (ClinicalTrials.gov record NCT04175600, source copy `cardio:ctgov-nct04175600-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04175600-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
- Acronym: SALTO
- Condition: Hypertension, Pulmonary
- Intervention (Drug): Selexipag
- Intervention (Drug): Placebo
- Intervention (Drug): Standard of Care (SOC): Endothelin receptor antagonist
- Intervention (Drug): SOC: Phosphodiesterase type 5 (PDE-5) inhibitor
- Intervention (Drug): SOC: Soluble guanylate cyclase stimulator
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: 8c546d47f62ff3fb6715108bf661eafc064d814978ab8700db891d633a48bd84
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
